Adults with type 2 diabetes who initiate SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection have a ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

Canagliflozin is generally well tolerated and improves blood sugar control in children and adolescents with type 2 diabetes, ...

Germany: A retrospective cohort study has found that prior use of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM) ...

As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, ...

Empowering choice in the pharmacological management of type 2 diabetes One in nine people worldwide lives with diabetes, with 90% affected by type 2 diabetes.1 Despite ongoing advances in therapy and ...

This latest approval builds on an earlier liquid formulation of generic methimazole for feline hyperthyroidism, which ...

Children and adolescents with type 2 diabetes had greater reductions in HbA1c with an oral SGLT2 inhibitor compared with ...

Polyuria and polydipsia (PU/PD)—excessive urination and thirst/drinking—are common concerns in cats with diabetes.

A randomized controlled trial investigated use of sodium glucose cotransporter 2 inhibitors (SGLT2i) on top of standard care immunosuppression in lupus nephritis.

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

There is lower risk for recurrent HF hospitalization in older patients that receive SGLT2is following acute decompensated heart failure.